Optimizing Outcomes for Patients With Soft-Tissue Sarcoma Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

J Adv Pract Oncol · 2018 · PMC6333558

Europe PMC

hedged sentence

0.0615

closest p · 1.2× alpha

0.0615

boldest claim

The sentences

showed a trendp = .0615so close (0.05 < p ≤ 0.1)

In a phase Ib/II randomized trial, the addition of olaratumab to doxorubicin failed to improve the primary endpoint of PFS compared with doxorubicin alone, but showed a trend toward improvement (6.6 vs. 4.1 months, p = .0615).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.